Harrow Health Inc Stock Price, News & Analysis

Harrow Health, Inc. (Nasdaq: HROW) will release its financial results for Q2 ended June 30, 2022 on August 9, 2022, after market close. A Letter to Stockholders will be available on its website. Following this, a conference call will occur at 4:45 p.m. ET to discuss the results and provide a business update. Investors can participate through dial-in or via live webcast. The telephonic replay will be available until August 16, 2022, and the webcast replay until November 9, 2022.

Harrow Health, Inc. (NASDAQ: HROW) has successfully transferred the New Drug Applications (NDAs) for three FDA-approved ophthalmic medicines: IOPIDINE® 1%, MAXITROL® 3.5mg/10,000 units/0.1%, and MOXEZA® 0.5%. Both IOPIDINE 1% and MAXITROL are now commercially available, with MOXEZA set for later release. This move follows their acquisition of these products in December 2021, during which Harrow began receiving net profits from sales. CEO Mark L. Baum expressed optimism about market interest and plans for commercial strategies targeting healthcare professionals and payers.

Harrow Health (NASDAQ: HROW) reported a record revenue of $22.1 million for Q1 2022, marking a 43% increase from $15.4 million in Q1 2021. The gross profit reached $16.2 million, up 38% year-over-year. A total of 689,000 product units were shipped, a 72% increase from the prior year. Despite a net loss of $2.4 million, the company anticipates a strong year driven by organic growth and plans for AMP-100's FDA review on October 16, 2022. Cash and equivalents stood at $42 million as of March 31, 2022.

Melt Pharmaceuticals announced favorable top-line results from its phase 1 PK study of MELT-210, a 3 mg sublingual midazolam tablet. The study involving 23 patients compared MELT-210 with IV midazolam and achieved concentration goals. CEO Larry Dillaha expressed optimism about the results, viewing it as a milestone for an IV-free sedation option. The next step includes discussions with the FDA regarding further clinical development. MELT-210 utilizes Catalent's proprietary Zydis® technology, with no FDA-approved equivalent products.

NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow Health, Inc. (NASDAQ: HROW) announced participation in B. Riley Securities' Annual Neuro & Ophthalmology Investor Conference. CEO Mark L. Baum and CFO Andrew Boll will present virtually on April 27, 2022, at 2:00 p.m. ET. A live webcast will be accessible on Harrow's website, with a replay available post-event. Harrow Health focuses on ophthalmic healthcare, owning ImprimisRx and Visionology, and holds equity in Eton Pharmaceuticals, Surface Ophthalmics, and Melt Pharmaceuticals.

Harrow Health, Inc. (Nasdaq: HROW) will release its financial results for Q1 2022 on May 5, 2022, post market close. The company, which focuses on ophthalmic healthcare, will also host a conference call at 4:45 PM ET to discuss the results and provide a business update. A webcast will be available for replay until August 5, 2022. Details of the event, including participation dial-ins and replay options, can be found on their website. This update is pertinent for investors and stakeholders tracking financial performance and corporate developments.

Harrow Health, Inc. (HROW) has appointed Perry J. Sternberg and Dr. Marty Makary to its Board of Directors, effective immediately, while Robert J. Kammer has resigned. Sternberg brings extensive commercial experience from leading eye care companies, and his expertise in strategic marketing is expected to aid in launching new FDA-approved products like AMP-100. Dr. Makary, with a strong background in healthcare policy and innovation, aligns with the company's mission of making medicines accessible. This restructuring aims to strengthen governance and support Harrow's goal of becoming a leading U.S. eye care company.

Harrow Health, Inc. (NASDAQ: HROW) reported record revenues of $20.2 million for Q4 2021, marking a 38% increase year-over-year. Gross profit also reached $15.1 million, a 42% rise, with a gross margin of 75%. The FDA accepted the NDA for AMP-100 with a PDUFA target date of October 16, 2022. Commissions from DEXYCU® sales hit $1.0 million, driven by record unit volumes. The company ended 2021 with $42.2 million in cash and equivalents, providing a strong foundation for future growth.

Melt Pharmaceuticals announces the appointment of Brad Osborne as Chief Financial Officer, bringing over 20 years of finance experience, including a decade at Precigen. His expertise spans IPOs, M&A, and SEC compliance. Dr. Larry Dillaha, CEO, emphasizes Osborne's significant role in guiding the company through its ongoing Phase 2 efficacy study for MELT-300 and advancing their patented MELT technology. Melt focuses on non-intravenous and non-opioid sedation solutions, carved out from Harrow Health in 2019, catering to over 100 million medical procedures in the U.S.